Blocking effect of a monoclonal antibody against recombinant Pvs25 on sporozoite development in Anopheles sinensis

Clinical and Vaccine Immunology

Volumn 17, Issue 8, 2010, Pages 1183-1187

  Moon, Sung Ung ^a   Kim, Hyung Hwan ^b,c   Kim, Tong Soo ^d   Choi, Kyung Mi ^a   Oh, Chang Mi ^a   Ahn, Yong Joo ^b   Hwang, Seo Kyoung ^b   Sohn, Youngjoo ^e   Shin, E Hyun ^a   Kim, Hyuck ^c   Lee, Hyeong Woo ^a,f  

^a Korea Centers for Disease Control and Prevention   (South Korea)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Jungwon University   (South Korea)

^d Inha University School of Medicine   (South Korea)

^e Department of Computer and Electronic Physics   (South Korea)

^f UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PROTOZOAL PROTEIN; RECOMBINANT PROTEIN PVS25; UNCLASSIFIED DRUG; MALARIA VACCINE; MEMBRANE ANTIGEN; PARASITE ANTIGEN; PROTOZOON ANTIBODY; PVS25 PROTEIN, P VIVAX; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANOPHELES; ANOPHELES SINENSIS; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; MALARIA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE DEVELOPMENT; PLASMODIUM VIVAX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTOZOAL GENETICS; SOUTH KOREA; SPOROZOITE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; DISEASE CARRIER; DNA SEQUENCE; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; MOLECULAR CLONING; MOLECULAR GENETICS; MOLECULAR WEIGHT; PARASITOLOGY; PLASMODIUM VIVAX MALARIA;

ANIMALS; ANOPHELES; ANTIBODIES, MONOCLONAL; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ANTIGENS, SURFACE; CLONING, MOLECULAR; DISEASE VECTORS; ESCHERICHIA COLI; GENE EXPRESSION; HUMANS; MALARIA VACCINES; MALARIA, VIVAX; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; RECOMBINANT PROTEINS; REPUBLIC OF KOREA; SEQUENCE ANALYSIS, DNA; SPOROZOITES;

EID: 77955299123     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00101-10     Document Type: Article

References (25)

1. Arakawa, T., D. K. Chong, and W. H. Langridge. 1998. Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nat. Biotechnol. 16:292-297.
2. Barr, P. J., K. M. Green, H. L. Gibson, I. C. Bathurst, I. A. Quakyi, and D. C. Kaslow. 1991. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J. Exp. Med. 174:1203-1208.
3. Breman, J. G. 2001. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am. J. Trop. Med. Hyg. 64:1-11.
4. Duffy, P. E., P. Pimenta, and D. C. Kaslow. 1993. Pgs28 belongs to a family of epidermal growth factor-like antigens that are targets of malaria transmission-blocking antibodies. J. Exp. Med. 177:505-510.
5. Duffy, P. E., P. Pimenta, and D. C. Kaslow. 1997. A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect. Immun. 65:1109-1113.
6. Gozar, M. M. G., V. L. Price, and D. C. Kaslow. 1998. Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice. Infect. Immun. 60:59-64.
7. Harinasuta, T., P. Suntharasamai, and C. Viravan. 1965. Chloroquine-resistant falciparum malaria in Thailand. Lancet ii:657-660.
8. Hisaeda, H., A. W. Stowers, T. Tsuboi, W. E. Collins, J. S. Sattabongkot, and N. Suwanabun. 2000. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect. Immun. 68:6618-6623.
9. Kapturczak, M. H., C. Wasserfall, T. Brusko, M. Campbell-Thompson, T. M. Ellis, M. A. Atkinson, and A. Agarwal. 2004. Heme oxygenase-1 modulates early inflammatory responses: evidence from the heme oxygenase-1-deficient mouse. Am. J. Pathol. 165:1045-1053.
10. Kaslow, D. C., I. A. Quakyi, C. Syin, M. G. Raum, D. B. Keister, and J. E. Coligan. 1988. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature 333:74-76.
11. Lee, H. W., E. H. Shin, S. H. Cho, H. I. Lee, C. L. Kim, W. G. Lee, S. U. Moon, J. S. Lee, W. J. Lee, and T. S. Kim. 2002. Detection of vivax malaria sporozoites naturally infected in anopheline mosquitoes from endemic areas of northern parts of Gyeonggi-do (Province) in Korea. Kor. J. Parasitol. 40:75-81.
12. National Malaria Eradication Service. 1966. Malaria pre-eradication program in Korea. Progress report 1961-1965, p. 44-70. Ministry of Health and Social Affairs, Seoul, Republic of Korea.
13. Paik, Y. H., H. I. Ree, and J. C. Shim. 1988. Malaria in Korea. Jpn. J. Exp. Med. 58:55-66.
14. Rieckmann, K. H., D. R. Davis, and C. D. Hutton. 1989. Plasmodium vivax resistance to chloroquine? Lancet ii:1183-1184.
15. Roberts, D. R., and R. G. Andre. 1994. Insecticide resistance issues in vector borne disease control. Am. J. Trop. Med. Hyg. 50:21-34.
16. Rosenberg, R., and J. Rungsiwongse. 1991. The number of sporozoites produced by individual malaria oocysts. Am. J. Trop. Med. Hyg. 45:574-577.
17. Sattabongkot, J., T. Tsuboi, H. Hisaeda, M. Tachibana, N. Suwanabun, T. Rungruang, Y. M. Cao, A. W. Stowers, J. Sirichaisinthop, R. E. Coleman, and M. Torii. 2003. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates. Am. J. Trop. Med. Hyg. 69:536-541.
18. Soh, J. T., K. T. Lee, K. Y. Im, D. Y. Min, M. H. Ahn, J. J. Kim, and T. S. Yong. 1985. Current status of malaria in Korea. Yonsei Rep. Trop. Med. 16:11-18.
19. Sun, J. B., J. Holmgren, and C. Czerkinsky. 1994. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc. Natl. Acad. Sci. U. S. A. 91:10795-10799.
20. Taylor, D., N. Cloonan, V. Mann, Q. Cheng, and A. Saul. 2000. Sequence diversity in rodent malaria of the Pfs28 ookinete surface antigen homologs. Mol. Biol. Parasitol. 110:429-434.
21. Tsuboi, T., D. C. Kaslow, M. M. Gozar, M. Tachibana, Y. M. Cao, and M. Torii. 1998. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol. Med. 4:772-782.
22. Tsuboi, T., Y. M. Cao, Y. Hitsumoto, T. Yanagi, and H. Kanbara. 1997. Two antigens of zygotes and ookinetes of Plasmodium yoelii and Plasmodium bergei that are distinct targets of transmission-blocking immunity. Infect. Immun. 65:2260-2264.
23. Wang, L., L. Kedzierski, S. L. Wesselingh, and R. L. Coppel. 2003. Oral immunization with a recombinant malaria protein induces conformational antibodies and protects mice against lethal malaria. Infect. Immun. 71:2356-2364.
24. World Health Organization. 1997. World malaria situation in 1994. I. Population at risk. Wkly. Epidemiol. Rec. 72:269-274.
25. Zakeri, S., S. Razavi, and N. D. Djadid. 2009. Genetic diversity of transmission blocking vaccine candidate (Pvs25 and Pvs28) antigen in Plasmodium vivax clinical isolates from Iran. Acta Trop. 109:176-180.